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Abstract Lysosomal ß-galactosidase precursor is processed to a 
mature form and associated with protective protein in lysosomes. 
In this study we used two cysteine protease proinhibitors, E64-d 
for cathepsins B, S, H, and L, and CA074Me for cathepsin B. 
They are converted intracellularly to active forms, E-64c and 
CA074, respectively. Both active compounds inhibited matura-
tion of the exogenous ß-galactosidase precursor, but E-64c did 
not inhibit further degradation to an inactive 50-kDa product. 
We concluded that cathepsin B participated exclusively in 
maturation of ß-galactosidase, and a non-cysteine protease was 
involved in further degradation and inactivation of the enzyme 
molecule. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Lysosomal ß-galactosidase (EC 3.2.1.23) is primarily defi-
cient in ß-galactosidosis represented by GMi-gangliosidosis 
and Morquio B disease [1], and secondarily deficient in ga-
lactosialidosis that is caused by the primary defect of protec-
tive protein (cathepsin A; EC 3.4.16.1) [2]. ß-Galactosidase is 
synthesized as an 86-kDa precursor that is processed to a 64-
kDa mature form by lysosomal proteases. Early in this proc-
essing, ß-galactosidase forms a stable complex with protective 
protein, and becomes protected against degrading proteases 
[3,4]. The level of intracellular ß-galactosidase activity is there-
fore regulated by lysosomal proteases responsible for matura-
tion of the precursor and for ultimate degradation. Details of 
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this molecular regulation are not known at present, but our 
previous studies indicated that two different proteases were 
suggested to be involved in processing of the enzyme: one 
inhibited by leupeptin and the other not inhibited by leupeptin 
[5,6]. 
Lysosomes in mammalian cells contain several cysteine pro-
teases; cathepsin B (EC 3.4.22.1), cathepsin H (EC 3.4.22.16), 
and cathepsin L (EC 3.4.22.15) in most tissues [7], and also 
cathepsin S (EC 3.4.22.27) in some tissues [8]. Cathepsin B has 
been shown to be involved in processing of protein precursors 
[9-11], antigen presentation [12], and tumor metastasis [13]. 
Cathepsin L is involved in bone resorption [14]. However, 
little is known about their authentic intracellular substrates. 
Recently, a proinhibitor, CA074Me [15], has become available 
for the study of intracellular protein turnover. It is almost 
inactive itself, but rapidly de-methylated intracellularly to an 
active form, CA074, a highly specific inhibitor of cathepsin B. 
It has little effect on cathepsin H, L, S, or m-calpain (EC 
3.4.22.17) [16,17]. Another cysteine protease proinhibitor, 
E64-d, after being converted to an active form, E64-c, shows 
more generalized inhibitory effects [18], including cathepsin B. 
They should allow us to specify the function of cathepsin B in 
proteolytic processing of exogenous ß-galactosidase precursor 
in ß-galactosidase-deficient fibroblasts, where the precursor 
enzyme is endocytosed via the mannose 6-phosphate receptor 
(MPR) and transported to lysosomes in these cells [19-21]. 
In this report we demonstrated that both E64-d and 
CA074Me inhibited maturation of the ß-galactosidase precur-
sor, but further degradation was not inhibited. This result 
indicated that cathepsin B is involved in processing of the 
ß-galactosidase precursor and another non-cysteine protease 
is present for further degradation. 
2. Experimental procedures 
2.1. Materials 
CA074Me and E64-d were obtained from Taisho Pharmaceutical 
Co. (Tokyo, Japan). The expression vector, pCAGGS-neo, was pro-
vided by Dr. J. Miyazaki (University of Tokyo) [22]. Pepstatin A, 
chymostatin, and Z-Arg-Arg-AMC were purchased from Peptide In-
stitute (Osaka, Japan); 4-methylumbelliferone (4MU) from Nacalai 
Tesque (Kyoto); restriction enzymes and T4 DNA ligase from Takara 
Shuzo (Tokyo); Lipofectin, G418, Ham's F-10 medium and fetal bo-
vine serum from Gibco BRL (Grand Island, NY); Enhanced Chem-
iluminescence (ECL) for Western blotting from Amersham (Bucking-
hamshire) ; and mannose-6-phosphate (M6P) and goat anti-rabbit IgG 
peroxidase conjugate from Sigma (St. Louis, MO). 
2.2. Cell strains 
We used three different fibroblast strains with primary ß-galactosi-
dase deficiency (ß-galactosidosis) for this study. Cell strain 1, from a 
patient with infantile GMi-gangliosidosis, was homozygous for dupli-
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cation of nucleotides 1103-1226 [23]. ß-Galactosidase activity was not 
detectable. Cell strain 2 was from another patient with infantile GMI-
gangliosidosis. Gene mutation has not yet been identified. The resid-
ual enzyme activity was 1.7% of the control mean. Cell strain 3, from 
a patient with Morquio B disease, was homozygous for the W273L 
mutation. The residual enzyme activity was 4.9% of the control mean. 
A fibroblast strain from a patient with an unknown neurological dis-
ease and negative metabolic screening was used as a control for this 
study. They were cultured in Ham's F-10 medium supplemented with 
10% fetal bovine serum and antibiotics. 
2.3. Enzyme assay and protein determination 
ß-Galactosidase and a-galactosidase were assayed with 4MU-ß-D-
galactopyranoside and 4MU-cc-D-galactopyranoside as substrates, re-
spectively [24]. Cathepsin B was assayed with Z-Arg-Arg-AMC, ac-
cording to the method of Barrett and Kirschke [7,24]. One unit rep-
resents one nmol of 4MU or AMC substrate released per hour. 
Protein in the soluble fraction of the fibroblast lysate was measured 
by the method of Bradford [25]. 
2.4. Preparation of recombinant ß-galactosidase precursor 
Recombinant ß-galactosidase precursor secreted from stably trans-
formed CHO cells was isolated as described previously [19], except 
that the expression vector pCAGGS-neo was used in this study. The 
cDNA for human ß-galactosidase [26] digested by San. was subcloned 
into the Xhol site of pCAGGS-neo. CHO cells were transfected with 
the plasmid using Lipofectin [27], and stable transformants were se-
lected by G418. The cells secreting the highest amount of the ß-ga-
lactosidase precursor into the medium were cloned and cultured at 
confluence for 6 days at 30°C. The culture medium containing 125 
U/ml of newly synthesized ß-galactosidase precursor was used for 
replacement studies (conditioned medium). The presence of the ß-ga-
lactosidase precursor was confirmed by Western blotting as previously 
described [19]. 
2.5. Intracellular processing of the exogenous ß-galactosidase precursor 
Cysteine protease proinhibitors were solubilized in dimethyl sulfox-
ide (DMSO), and added to the culture medium, with final concentra-
tions of 1-25 uM inhibitor and 0.5% DMSO. Confluent cells on 60-
mm dishes were pre-incubated in the presence of one of the protease 
proinhibitors for 3 h, then cultured for another 20 h in the presence of 
both the conditioned medium containing 500 units of the precursor 
and the protease inhibitor at the same concentration, and harvested 
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Fig. 1. Effects of protease inhibitors on uptake of exogenous re-
combinant ß-galactosidase precursor by ß-galactosidase fibroblasts. 
Enzyme-deficient fibroblasts were incubated for 3 h in the presence 
of protease inhibitors, where indicated. Cells were then incubated 
for up to 20 h in the culture medium containing ß-galactosidase 
precursor only (125 U/ml) (o), precursor and 10 mg/ml M6P (■), 
precursor and 25 uM CA074Me (•), and precursor and 25 uM 
E64-d ( A ) . Restoration of activity was inhibited by M6P or by 
CA074Me, but there was no effect with E64-d. The same result was 
obtained in two independent experiments. 
Fig. 2. Dose-dependent effect of protease inhibitors on restoration 
of enzyme activity in ß-galactosidase-deficient fibroblasts by exoge-
nous ß-galactosidase precursor. Enzyme-deficient fibroblasts were in-
cubated in the presence of 0.25 uM of CA074Me (■) or E64-d (□) 
as described in Fig. 1. Restoration was inhibited by CA074Me in a 
dose-dependent manner, but there was no effect with E64-d. Each 
value is expressed as mean ± S.E.M. (n = 3). 
by scraping. Cell lysates were subjected to enzyme assays and Western 
blotting. 
2.6. Western blotting 
For electrophoresis 30 u.g of protein was applied to each lane of the 
8% SDS-polyacrylamide gel. Western blotting was performed with the 
anti-recombinant precursor ß-galactosidase IgG (1:750 dilution) [6] 
and ECL as described before [6,28]. 
3. Results 
The enzymatically active recombinant precursor [19] was 
taken up by infantile GMi-gangliosidosis fibroblasts (cell 
strain 1), and restored the enzyme activity after 20 h of in-
cubation (Fig. 1). This uptake was inhibited in the presence of 
M6P (Fig. 1). The enzyme activity was not restored in galac-
tosialidosis fibroblasts (data not shown). CA074Me inhibited 
the restoration of enzyme activity, but E64-d did not (Fig. 1). 
The effect of CA074Me was dose-dependent (Fig. 2). 
The enzyme activity was slightly elevated in the cells 
(1023 ±79 nmol/h/mg protein) after incubation for 72 h in 
the culture medium containing E64-d (10 (ig/ml), as compared 
with the activity in control cells without addition of the in-
hibitor (656 ±60 nmol/h/mg protein). Chymostatin and pep-
statin A had no activating effect (754 ± 30 and 611 ± 55 nmol/ 
h/mg protein, respectively). 
For analysis of intracellular turnover of the exogenous pre-
cursor, we used the cell strain 1 that had no detectable resid-
ual activity and expressed only a trace of detectable enzyme 
protein by Western blotting (Fig. 3, lane 1). The endocytosed 
86-kDa ß-galactosidase precursor was incorporated into the 
cells and rapidly processed to the 64-kDa mature form (Fig. 3, 
lane 2). A small portion of the mature enzyme was further 
degraded to a 50-kDa protein (Fig. 3, lane 2). This 50-kDa 
protein was also observed in untreated normal fibroblasts 
(Fig. 3, lane 5). 
When the cells were cultured with CA074Me, the ß-galac-
tosidase precursor remained unprocessed or was degraded to 
the 50-kDa protein, and normal processing to the 64-kDa 
protein was almost completely inhibited (Fig. 3, lane 3). In 
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Fig. 3. Proteolytic maturation of the exogenous precursor was al-
tered by cysteine protease inhibitors. Enzyme-deficient fibroblasts 
were incubated for 20 h with 125 U/ml ß-galactosidase precursor 
(lane 2); precursor and 25 uM CA074Me (lane 3); or precursor and 
25 uM E64-d (lane 4) after 3-h preincubation with each inhibitor; 
or in the absence of precursor or inhibitor (lane 1). Normal fibro-
blasts also were incubated without protease inhibitor (lane 5). Cell 
lysates (30 mg of protein) were subjected to SDS-8% polyacrylamide 
gel electrophoresis and blotted onto nitrocellulose membrane as de-
scribed in the text. Autoradiography: 2 min. No cross-reacting ma-
terial was detectable in the control (lane 1). The recombinant 86-
kDa ß-galactosidase precursor was processed to the mature 64-kDa 
form and degraded to a major product at 50 kDa (lane 2). In the 
presence of 25 uM CA074Me, the total intracellular enzyme was de-
creased as compared to that in control cells only for the ß-galacto-
sidase precursor, and the degraded 50-kDa form was detectable 
(lane 3). With 25 (xM E64-d, precursor processing was slowed down 
with little mature form detected. Degradation of the ß-galactosidase 
precursor to the 50-kDa product was not inhibited (lane 4). 
the presence of E64-d (Fig. 3, lane 4), most of the endocytosed 
enzyme was either unprocessed or was degraded to the 50-
kDa protein, although the mature enzyme also appeared in 
relatively small amount. 
Cathepsin B activity was completely inhibited after incuba-
tion for 23 h with 10 uM CA074Me and almost completely 
with 10 \xM E64-d (Table 1). oc-Galactosidase activity was not 
affected in this experiment (Table 1). This result excluded the 
possibility of a generalized cytotoxic effect of CA074Me or 
E64-d in the range of 1-25 U.M on cultured fibroblasts, caus-
ing a decrease in protease activities and inhibition of normal 
processing of the enzyme molecule. 
4. Discussion 
Lysosomal ß-galactosidase is synthesized as an 86-kDa pre-
cursor, transported to lysosomes, associated with neuramini-
dase and protective protein, and then processed to the mature 
form. This maturation is achieved by removal of a 20-kDa 
peptide from the carboxy-terminal end of the precursor mol-
ecule [29]. In galactosialidosis, the complex formation is im-
paired due to a defect in protective protein expression, and 
rapid proteolysis of ß-galactosidase and neuraminidase en-
sues. The molecular mechanism is not known for stabilization 
and activation of ß-galactosidase and neuraminidase in the 
complex [30,31]. 
Leupeptin protects ß-galactosidase against proteolysis at 
the position 82 residues upstream of the C-terminal. In fact, 
it restores ß-galactosidase activity in galactosialidosis fibro-
blasts [3,5,6,24,32]. This restoration is also observed in the 
presence of protective protein. It is not known whether or 
not protective protein is involved directly in posttranslational 
processing of ß-galactosidase [6,33]. 
Enzyme loading experiments provide further information 
about processing of the ß-galactosidase protein under physio-
logical conditions in the presence of functionally active pro-
tective protein [6,19-21]. Recombinant ß-galactosidase precur-
sor in the culture medium is recognized by MPR, endocytosed 
into the post-Golgi compartment of human ß-galactosidosis 
fibroblasts, and converted to the mature form [21]. On the 
other hand, transient expression of ß-galactosidase cDNA in 
COS-1 cells produces a large amount of the 86 kDa ß-galac-
tosidase precursor, but only a small portion of this precursor 
is processed to the 64-kDa mature form [26]. Permanently 
transformed CHO cells also express the ß-galactosidase pre-
cursor, which is processed to a mature 64-kDa protein but 
rapidly degraded to an inactive 50-kDa product [6]. 
Lipophilic pro-inhibitors used in this study, CA074Me and 
E64-d, have no direct effect on proteases, but they are con-
verted to active forms, CA074 and E64-c, respectively, in cul-
tured fibroblasts [15,18]. E64-c inhibits several cysteine endo-
peptidases, such as lysosomal cathepsin B, L, H, and 
cytoplasmic calpains [15,18], but CA074 preferentially inhibits 
cathepsin B [16,17]. In this study, we demonstrated that 
CA074Me in the culture medium caused a relatively little 
accumulation of the exogenous ß-galactosidase precursor 
and inhibited its processing to the mature form in GMi-gan-
gliosidosis fibroblasts. Cathepsin B also may have accelerated 
endocytosis of the enzyme, and its inactivation may have re-
sulted in low uptake of the precursor protein. E64-d did not 
affect uptake of the ß-galactosidase precursor, and more pre-
cursor remained unprocessed although subsequent degrada-
tion to the 50-kDa polypeptide was not impaired. 
These results indicated that E64-d inhibited processing of 
Table 1 
Effects of protease inhibitors on lysosomal enzymes 
Addition (UM) Cathepsin B 
Mean±S.E.M. 
1247 ±85 
53 ±6 
-
-
91 ±6 
17±2 
-
(%) 
(100) 
(4) 
(0) 
(0) 
(7) 
(1) 
(0) 
a-Galactosidase 
Mean±S.E.M. 
125±21 
137 ±39 
141 ±33 
114± 13 
151 ±20 
203 ± 39 
121 ±31 
(%) 
(100) 
(109) 
(113) 
(91) 
(121) 
(163) 
(96) 
None 
CA074Me 
CA074Me 
CA074Me 
E64-d 
E64-d 
E64-d 
1 
10 
25 
1 
10 
25 
Fibroblasts with ß-galactosidosis (#1-3) were pre-incubated for 3 h in the presence of cysteine protease. This was followed by a 20-h incubation in 
the conditioned medium containing 125 U/ml of recombinant precursor ß-galactosidase, and 0-25 uM of cysteine protease inhibitors (dissolved in 
0.5% DMSO). Enzyme activity was expressed as unit/mg protein (rc = 3). -, not detected. 
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the ß-galactosidase precursor but did not inhibit degradation 
to the 50-kDa protein. In the presence of CA074Me, little 
precursor, mature, or degenerative product appeared, suggest-
ing a rapid turnover of ß-galactosidase without forming a 
stable complex with protective protein as observed in galacto-
sialidosis [6]. We concluded that cathepsin B, which is inhib-
ited by CA074 and E64-c, is active in maturation of ß-galac-
tosidase, and at least one non-cysteine protease, unaffected by 
E64-c, degraded the precursor to the 50-kDa protein. Chy-
mostatin (serine protease inhibitor) or pepstatin A (aspartic 
protease inhibitor) had no effect on processing of the ß-gal-
actosidase precursor (data not shown). 
Cathepsin B is a major lysosomal protease, whose enzy-
matic properties have been intensively studied in vitro [7,34], 
and its crystal structure was determined [35]. It exhibits both 
endopeptidase and dipeptidyl carboxypeptidase activities in 
vitro [7,36]. However, its role in intralysosomal maturation 
of hydrolases has been poorly defined [9,10]. Our results point 
to an important role of cathepsin B in maturation of lysoso-
mal hydrolases. The candidate cleavage point in conversion of 
the ß-galactosidase precursor to the mature form has been 
proposed as Arg-530 in a uniquely hydrophilic sequence 
[29], which is acceptable as a PI for endopeptidase cathepsin 
B [7,10,35]. Limited proteolysis of the recombinant ß-galacto-
sidase precursor with pepsin or with purified cathepsin B with-
out protective protein could not produce the mature form 
(Callahan, J.W., unpublished data). To date no one has pre-
sented definitive evidence of the true C-terminus of the mature 
enzyme, and it remains unclear how many steps are involved 
in normal C-terminal processing. Development of specific in-
hibitors for proteases will solve this problem. The present 
study using protease inhibitors suggested the role of specific 
cathepsins in processing of ß-galactosidase, and serves as a 
model system for the study of posttranslational events and 
protein-protein interactions in lysosomes, not only for ß-ga-
lactosidase but also for other lysosomal enzymes. 
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